ArticleCardiovascular diabetology2014

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.

Bowen Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.